Is inflammation good, bad or irrelevant for skeletal muscles in COPD?

Thorax

Volumn 63, Issue 2, 2008, Pages 95-96

  Sin, Don D ^a,b   Reid, W Darlene ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULOTROPIN;

CATABOLISM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; EDITORIAL; EXERCISE; INFLAMMATION; LIMB WEAKNESS; MORBIDITY; MORTALITY; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE FUNCTION; MUSCLE WEAKNESS; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PULMONARY REHABILITATION; SKELETAL MUSCLE; SMOKING CESSATION;

HUMANS; INFLAMMATION MEDIATORS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYOSITIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 39049110761     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.088575     Document Type: Editorial

References (16)

1. Decramer M, Gosselink R, Troosters T, et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997;10:417-23.
2. Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007;62:115-20.
3. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 2002;57:1067-70.
4. Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006;61:17-22.
5. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006;61:10-16.
6. Langen RC, Schols AM, Kelders MC, et al. Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol 2006;35:689-96.
7. Barreiro E, Schols AMWJ, Polkey MI, et al. Cytokine profile in quadriceps muscles of patients with severe chronic obstructive pulmonary disease. Thorax 2008;63:100-7.
8. Chen SE, Jin B, Li YP. TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol 2007;292:C1660-71.
9. Tayek JA. Effects of tumor necrosis factor alpha on skeletal muscle amino acid metabolism studied in-vivo. J Am Coll Nutr 1996;15:164-8.
10. Contreras-Shannon V, Ochoa O, Reyes-Reyna SM, et al. Fat accumulation with altered inflammation and regeneration in skeletal muscle of CCR2-/- mice following ischemic injury. Am J Physiol Cell Physiol 2007;292:C953-67.
11. Alvarez B, Quinn LS, Busquets S, et al. Direct effects of tumor necrosis factor alpha (TNF-alpha) on murine skeletal muscle cell lines. Bimodal effects on protein metabolism. Eur Cytokine Netw 2001;12:399-410.
12. Montes de Oca M, Torres SH, De Sanctis J, et al. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Hespir J 2005;26:390-7.
13. Gosker HR, Wouters EF, van der Vusse GJ, et al. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr 2000;71:1033-47.
14. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30.
15. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
16. Marsolais D, Duchesne E, Cote CH, et al. Inflammatory cells do not decrease the ultimate tensile strength of intact tendons in vivo and in vitro: protective role of mechanical loading. J Appl Physiol 2007;102:11-17.